Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 192
Inquire Before Buying

Global Markets Direct's, ‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

  • The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

  • The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Keratoconjunctivitis sicca (Dry Eye) Overview 9
Therapeutics Development 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 11
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 12
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes 16
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 21
Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes 25
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 26
AB2 Bio Ltd. 26
Allergan Plc 27
Ascendia Pharmaceuticals LLC 28
Chong Kun Dang Pharmaceutical Corp. 29
Digna Biotech, S.L. 30
Dompe Farmaceutici S.p.A. 31
HanAll Biopharma Co., Ltd. 32
Herantis Pharma Plc 33
Huons Co., Ltd. 34
InSite Vision Incorporated 35
Kala Pharmaceuticals, Inc. 36
Kissei Pharmaceutical Co., Ltd. 37
KPI Therapeutics, Inc. 38
Kukje Pharmaceutical Industry Co., Ltd. 39
Laboratoires Thea S.A. 40
Lee's Pharmaceutical Holdings Limited 41
Lipicard Technologies Limited 42
Merck & Co., Inc. 43
Mimetogen Pharmaceuticals Inc. 44
Mitotech S.A. 45
Nanomerics Ltd 46
Neuroptis Biotech 47
Novaliq GmbH 48
Ocular Therapeutix, Inc. 49
Oculis ehf 50
OncoNOx ApS 51
Otsuka Holdings Co., Ltd. 52
Parion Sciences, Inc. 53
Quorum Innovations LLC 54
RegeneRx Biopharmaceuticals, Inc. 55
Rigel Pharmaceuticals, Inc. 56
Samjin Pharmaceutical Co., Ltd. 57
Santen Pharmaceutical Co., Ltd. 58
Seikagaku Corporation 59
Sucampo Pharmaceuticals, Inc. 60
TearSolutions, LLC. 61
TopiVert Ltd 62
Xigen SA 63
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Target 65
Assessment by Mechanism of Action 69
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
AGN-223575 - Drug Profile 77
AGN-232411 - Drug Profile 78
Androgen Tears - Drug Profile 79
AVA-3486 - Drug Profile 80
AVX-012 - Drug Profile 81
BRM-421 - Drug Profile 82
cinhyaluronate sodium - Drug Profile 83
Cis-Urocanic Acid - Drug Profile 84
cyclosporine - Drug Profile 87
cyclosporine - Drug Profile 90
cyclosporine - Drug Profile 92
cyclosporine - Drug Profile 93
cyclosporine - Drug Profile 94
cyclosporine - Drug Profile 95
cyclosporine - Drug Profile 96
cyclosporine - Drug Profile 97
cyclosporine SR - Drug Profile 98
dexamethasone acetate SR - Drug Profile 99
diclofenac sodium - Drug Profile 104
diquafosol tetrasodium - Drug Profile 105
disitertide - Drug Profile 107
Drugs to Agonize FPR2 for Dry Eye - Drug Profile 109
Elate Ocular - Drug Profile 110
HL-036 - Drug Profile 111
HU-007 - Drug Profile 112
hyaluronate sodium - Drug Profile 113
ISV-101 - Drug Profile 114
K-089 - Drug Profile 115
KeraKlear - Drug Profile 116
KJ-14003 - Drug Profile 117
KL-7016 - Drug Profile 118
KPI-190 - Drug Profile 119
Lacripep - Drug Profile 120
LME-636 - Drug Profile 121
loteprednol etabonate - Drug Profile 122
LT-4002 - Drug Profile 125
LT-4003 - Drug Profile 126
NOP-3 - Drug Profile 127
NOP-5 - Drug Profile 128
Nov-03 - Drug Profile 129
OC-301 - Drug Profile 130
OX-1001 - Drug Profile 131
ozagrel - Drug Profile 132
P-321 - Drug Profile 133
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 135
PPL-003 - Drug Profile 137
Qi-204 - Drug Profile 139
R-348 - Drug Profile 140
rebamipide - Drug Profile 142
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 144
RGN-259 - Drug Profile 146
RP-101 - Drug Profile 153
RU-101 - Drug Profile 154
SA-001 - Drug Profile 156
SJP-002 - Drug Profile 157
Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile 158
ST-266 - Drug Profile 159
tadekinig alfa - Drug Profile 161
tavilermide hydrochloride - Drug Profile 162
TOP-1630 - Drug Profile 164
XG-104 - Drug Profile 165
ZK-003 - Drug Profile 166
zucapsaicin - Drug Profile 167
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 169
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 175
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 176
Featured News & Press Releases 176
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H2 2016 30
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2016 31
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 32
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 33
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2016 34
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 35
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 36
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2016 37
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2016 38
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2016 39
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 40
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 41
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics, Inc., H2 2016 42
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 43
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea S.A., H2 2016 44
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 45
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2016 46
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2016 47
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016 48
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H2 2016 49
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2016 50
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2016 51
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2016 52
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2016 53
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2016 54
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2016 55
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 56
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2016 57
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2016 58
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 59
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 60
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2016 61
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 62
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2016 63
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 64
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2016 65
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2016 66
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2016 67
Assessment by Monotherapy Products, H2 2016 68
Number of Products by Stage and Target, H2 2016 70
Number of Products by Stage and Mechanism of Action, H2 2016 74
Number of Products by Stage and Route of Administration, H2 2016 78
Number of Products by Stage and Molecule Type, H2 2016 80
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2016 173
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H2 2016 174
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H2 2016 175
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H2 2016 176
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H2 2016 177
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..5), H2 2016 178
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2016 179

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 68
Number of Products by Top 10 Targets, H2 2016 69
Number of Products by Stage and Top 10 Targets, H2 2016 69
Number of Products by Top 10 Mechanism of Actions, H2 2016 73
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 73
Number of Products by Top 10 Routes of Administration, H2 2016 77
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 77
Number of Products by Molecule Types, H2 2016 79
Number of Products by Stage and Molecule Types, H2 2016 79
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Global Latanoprost Sales Market Report 2017
    Published: 13-Jan-2017        Price: US 4000 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Latanoprost Revenue, means the sales value of Latanoprost This report studies sales (consumption) of Latanoprost in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Pfizer - Teva Pharmaceuticals - Greenstone - Novartis - Mylan - ......
  • China Ophthalmic Drug Market Research Report 2017
    Published: 13-Jan-2017        Price: US 3200 Onwards        Pages: 114
    Notes: Sales, means the sales volume of Ophthalmic Drug Revenue, means the sales value of Ophthalmic Drug This report studies Ophthalmic Drug in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Novartis - Allergan - Santen - Pfizer - Merck - Roche - Bayer - Senju - Regeneron - Valeant - Ozur......
  • Glaucoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Glaucoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Glaucoma Report is to understand the market and pipeline status of the drugs around the Glaucoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline sta......
  • Bacterial Conjunctivitis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Bacterial Conjunctivitis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Bacterial Conjunctivitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collabora......
  • Retinal Degeneration-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Retinal Degeneration-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Retinal Degeneration. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Retinal Vein Occlusion-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Retinal Vein Occlusion-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Retinal Vein Occlusion. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Retinitis Pigmentosa (Retinitis). The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, lice......
  • Retinopathy Of Prematurity-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Retinopathy Of Prematurity-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Retinopathy Of Prematurity. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, colla......
  • Macular Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Macular Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Macular Edema Report is to understand the market and pipeline status of the drugs around the Macular Edema to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs